Pascal Deschatelets's most recent trade in Apellis Pharmaceuticals Inc was a trade of 82,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 82,500 | 82,500 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 12,780 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 21 May 2025 | 12,780 | 1,160,496 (1%) | 0% | 3.8 | 48,053 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.52 per share. | 29 Jan 2025 | 826 | 1,147,716 (1%) | 0% | 29.5 | 24,386 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.43 per share. | 22 Jan 2025 | 3,948 | 1,148,542 (1%) | 0% | 30.4 | 120,120 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 15,045 | 1,152,490 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 29.96 per share. | 17 Jan 2025 | 750 | 1,137,445 (1%) | 0% | 30.0 | 22,469 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 28.70 per share. | 13 Jan 2025 | 2,288 | 1,138,195 (1%) | 0% | 28.7 | 65,670 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 24,500 | 12,780 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 20 May 2024 | 24,500 | 1,140,483 (1%) | 0% | 3.8 | 92,120 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2024 | 78,907 | 108,622 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 08 May 2024 | 78,907 | 1,194,890 (1%) | 0% | 4.3 | 340,089 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.15 per share. | 08 May 2024 | 56,335 | 1,138,555 (1%) | 0% | 42.2 | 2,374,543 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.85 per share. | 08 May 2024 | 22,472 | 1,116,083 (1%) | 0% | 42.8 | 962,903 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 44.03 per share. | 08 May 2024 | 100 | 1,115,983 (1%) | 0% | 44.0 | 4,403 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.76 per share. | 08 Apr 2024 | 69,107 | 1,185,090 (1%) | 0% | 3.8 | 259,842 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2024 | 69,107 | 37,280 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 54.12 per share. | 08 Apr 2024 | 64,379 | 1,120,711 (1%) | 0% | 54.1 | 3,483,966 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 54.92 per share. | 08 Apr 2024 | 4,728 | 1,115,983 (1%) | 0% | 54.9 | 259,639 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. | 08 Mar 2024 | 69,107 | 1,185,090 (1%) | 0% | 3.7 | 253,623 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2024 | 69,107 | 106,387 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 61.88 per share. | 08 Mar 2024 | 42,750 | 1,142,340 (1%) | 0% | 61.9 | 2,645,173 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 62.69 per share. | 08 Mar 2024 | 26,257 | 1,116,083 (1%) | 0% | 62.7 | 1,646,041 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 63.35 per share. | 08 Mar 2024 | 100 | 1,115,983 (1%) | 0% | 63.4 | 6,335 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 67.77 per share. | 12 Feb 2024 | 1,148 | 1,115,983 (1%) | 0% | 67.8 | 77,796 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 64.14 per share. | 29 Jan 2024 | 874 | 1,117,131 (1%) | 0% | 64.1 | 56,057 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 65.00 per share. | 22 Jan 2024 | 3,913 | 1,118,005 (1%) | 0% | 65.0 | 254,329 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 9,805 | 9,805 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2024 | 6,743 | 1,123,550 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Deschatelets Pascal | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 66.81 per share. | 16 Jan 2024 | 1,632 | 1,121,918 (1%) | 0% | 66.8 | 109,032 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Aug 2023 | 18,500 | 1,065,313 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2023 | 18,500 | 54,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.66 per share. | 08 Aug 2023 | 12,000 | 1,053,313 (1%) | 0% | 23.7 | 283,920 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2023 | 18,500 | 72,994 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 10 Jul 2023 | 18,500 | 1,058,813 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 84.55 per share. | 10 Jul 2023 | 12,000 | 1,046,813 (1%) | 0% | 84.6 | 1,014,600 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 18,500 | 91,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Jun 2023 | 18,500 | 1,052,313 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 91.35 per share. | 08 Jun 2023 | 12,000 | 1,040,313 (1%) | 0% | 91.4 | 1,096,200 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 May 2023 | 18,500 | 1,045,813 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2023 | 18,500 | 109,994 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 92.39 per share. | 08 May 2023 | 12,000 | 1,033,813 (1%) | 0% | 92.4 | 1,108,680 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Apr 2023 | 18,500 | 128,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 10 Apr 2023 | 18,500 | 1,039,313 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 78.21 per share. | 10 Apr 2023 | 12,000 | 1,027,313 (1%) | 0% | 78.2 | 938,520 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Mar 2023 | 18,500 | 146,994 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Mar 2023 | 18,500 | 1,032,813 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 63.79 per share. | 08 Mar 2023 | 12,000 | 1,020,813 (1%) | 0% | 63.8 | 765,480 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 14,023 | 14,023 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 9,886 | 1,015,508 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.50 per share. | 21 Feb 2023 | 1,195 | 1,014,313 (1%) | 0% | 58.5 | 69,908 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.21 per share. | 10 Feb 2023 | 1,134 | 1,005,622 (1%) | 0% | 51.2 | 58,072 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2023 | 18,500 | 165,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Feb 2023 | 18,500 | 1,018,756 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 54.45 per share. | 08 Feb 2023 | 12,000 | 1,006,756 (1%) | 0% | 54.5 | 653,400 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 27 Jan 2023 | 832 | 1,000,256 (1%) | 0% | 52.8 | 43,905 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.05 per share. | 20 Jan 2023 | 2,326 | 1,001,088 (1%) | 0% | 52.0 | 121,068 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 30,845 | 30,845 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 19,634 | 1,003,414 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2023 | 18,500 | 183,994 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 09 Jan 2023 | 18,500 | 995,780 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 46.08 per share. | 09 Jan 2023 | 12,000 | 983,780 (1%) | 0% | 46.1 | 552,960 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.67 per share. | 29 Dec 2022 | 7,000 | 977,280 (1%) | 0% | 3.7 | 25,690 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2022 | 7,000 | 220,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Dec 2022 | 18,500 | 982,280 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2022 | 18,500 | 202,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 47.50 per share. | 08 Dec 2022 | 12,000 | 970,280 (1%) | 0% | 47.5 | 570,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2022 | 18,500 | 220,994 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Nov 2022 | 18,500 | 975,780 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 46.47 per share. | 08 Nov 2022 | 12,000 | 963,780 (1%) | 0% | 46.5 | 557,640 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Oct 2022 | 18,500 | 239,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 10 Oct 2022 | 18,500 | 969,280 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 57.50 per share. | 10 Oct 2022 | 12,000 | 957,280 (1%) | 0% | 57.5 | 690,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2022 | 18,500 | 257,994 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Sep 2022 | 18,500 | 962,780 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 63.98 per share. | 08 Sep 2022 | 12,000 | 950,780 (1%) | 0% | 64.0 | 767,760 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Aug 2022 | 18,500 | 276,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Aug 2022 | 18,500 | 956,280 (1%) | 0% | 2.7 | 49,395 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 62.50 per share. | 08 Aug 2022 | 12,000 | 944,280 (1%) | 0% | 62.5 | 750,000 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2022 | 12,000 | 301,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 47.95 per share. | 08 Jul 2022 | 12,000 | 937,780 (1%) | 0% | 48.0 | 575,400 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Jul 2022 | 12,000 | 943,280 (1%) | 0% | 2.7 | 32,040 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Jul 2022 | 6,500 | 949,780 (1%) | 0% | 2.7 | 17,355 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2022 | 6,500 | 294,994 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 17 Jun 2022 | 33,005 | 931,280 (1%) | 0% | 2.7 | 88,123 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 33,005 | 313,494 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2022 | 12,000 | 352,999 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Jun 2022 | 12,000 | 903,775 (1%) | 0% | 2.7 | 32,040 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 44.09 per share. | 08 Jun 2022 | 12,000 | 891,775 (1%) | 0% | 44.1 | 529,080 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 08 Jun 2022 | 6,500 | 898,275 (1%) | 0% | 2.7 | 17,355 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2022 | 6,500 | 346,499 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Other type of transaction at price $ 0.00 per share. | 21 Apr 2022 | 11,250 | 0 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2022 | 4,000 | 364,999 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.67 per share. | 21 Apr 2022 | 4,000 | 895,775 (1%) | 0% | 2.7 | 10,680 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 44.43 per share. | 21 Apr 2022 | 4,000 | 891,775 (1%) | 0% | 44.4 | 177,720 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Other type of transaction at price $ 0.00 per share. | 21 Apr 2022 | 1,875 | 891,775 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.12 per share. | 10 Feb 2022 | 1,057 | 893,650 (1%) | 0% | 47.1 | 49,806 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.59 per share. | 28 Jan 2022 | 931 | 894,707 (1%) | 0% | 38.6 | 35,927 | Common Stock |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 36,951 | 36,951 | - | - | Stock Option (Right to Buy) | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2022 | 26,051 | 895,638 (1%) | 0% | 0 | Common Stock | |
| Apellis Pharmaceuticals Inc | Pascal Deschatelets | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 47.40 per share. | 24 May 2021 | 6,250 | 869,587 (1%) | 0% | 47.4 | 296,250 | Common Stock |